Hispolon from Phellinus linteus has antiproliferative effects via MDM2-recruited ERK1/2 activity in breast and bladder cancer cells

Food and Chemical Toxicology

Volumn 47, Issue 8, 2009, Pages 2013-2021

  Lu, Te Ling ^a   Huang, Guan Jhong ^a   Lu, Te Jung ^b   Wu, Jin Bin ^a   Wu, Chieh Hsi ^a   Yang, Tung Chuan ^c   Iizuka, Akira ^a,d   Chen, Yuh Fung ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Hispolon; MDM2; p21; p53; Ubiquitination

Indexed keywords

CASPASE 7; CYCLIN DEPENDENT KINASE INHIBITOR 1; ETOPOSIDE; HERBACEOUS AGENT; HISPOLON; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IC 50; MUSHROOM; PROTEIN DEGRADATION; UBIQUITINATION;

AGARICALES; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CASPASE 7; CATECHOLS; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; ENZYME INDUCTION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPRECIPITATION; INDICATORS AND REAGENTS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

INONOTUS LINTEUS; PHELLINUS;

EID: 68649089457     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2009.05.023     Document Type: Article

References (34)

1. Agelopoulos K., Kersting C., Korsching E., Schmidt H., Kuijper A., August C., Wulfing P., Tio J., Boecker W., van Diest P.J., et al. Egfr amplification specific gene expression in phyllodes tumours of the breast. Cell Oncol. 29 (2007) 443-451
2. A.A. Ali N., Jansen R., Pilgrim H., Liberra K., and Lindequist U. Hispolon, a yellow pigment from Inonotus hispidus. Phytochemistry 41 (1996) 927-929
3. Canman C.E., Gilmer T.M., Coutts S.B., and Kastan M.B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 9 (1995) 600-611
4. Chen W., He F.Y., and Li Y.Q. The apoptosis effect of hispolon from Phellinus linteus (Berkeley & Curtis) Teng on human epidermoid KB cells. J. Ethnopharmacol. 105 (2006) 280-285
5. Chen W., Zhao Z., Li L., Wu B., Chen S.-F., Zhou H., Wang Y., and Li Y.-Q. Hispolon induces apoptosis in human gastric cancer cells through a ROS-mediated mitochondrial pathway. Free Rad. Biol. Med. 45 (2008) 60-72
6. Delgado M.D., Vaque J.P., Arozarena I., Lopez-Ilasaca M.A., Martinez C., Crespo P., and Leon J. H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism. Oncogene 19 (2000) 783-790
7. Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., and Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275 (2000) 8945-8951
8. Germain M., Affar E.B., D'Amours D., Dixit V.M., Salvesen G.S., and Poirier G.G. Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J. Biol. Chem. 274 (1999) 28379-28384
9. Gleave M.E., and Monia B.P. Antisense therapy for cancer. Nat. Rev. Cancer 5 (2005) 468-479
10. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
11. Hui L., Abbas T., Pielak R.M., Joseph T., Bargonetti J., and Foster D.A. Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Mol. Cell Biol. 24 (2004) 5677-5686
12. Ikeguchi M., Ueda T., Fukuda K., Yamaguchi K., Tsujitani S., and Kaibara N. Expression of the murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment. Am. J. Clin. Oncol. 25 (2002) 454-459
13. Jones S.N., Hancock A.R., Vogel H., Donehower L.A., and Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA 95 (1998) 15608-15612
14. Li M., Zhang Z., Hill D.L., Chen X., Wang H., and Zhang R. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res. 65 (2005) 8200-8208
15. Li M., Zhang Z., Hill D.L., Wang H., and Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 67 (2007) 1988-1996
16. Lianes P., Orlow I., Zhang Z.-F., Oliva M.R., Sarkis A.S., Reuter V.E., and Cordon-Cardo C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl. Cancer Inst. 86 (1994) 1325-1330
17. Maya R., Balass M., Kim S.T., Shkedy D., Leal J.F., Shifman O., Moas M., Buschmann T., Ronai Z., Shiloh Y., et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15 (2001) 1067-1077
18. Mayo L.D., and Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 98 (2001) 11598-11603
19. Meek D.W., and Knippschild U. Posttranslational modification of MDM2. Mol. Cancer Res. 1 (2003) 1017-1026
20. Mo S., Wang S., Zhou G., Yang Y., Li Y., Chen X., and Shi J. Phelligridins C-F: cytotoxic pyrano[4,3-c][2]benzopyran-1,6-dione and furo[3,2-c]pyran-4-one derivatives from the fungus Phellinus igniarius. J. Nat. Prod. 67 (2004) 823-828
21. Momand J., Zambetti G.P., Olson D.C., George D., and Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
22. Nakazawa, Y., Koike, K., Kamijo, T., 2004. ERK activation by ARF causes p53/MDM2-independent apoptotic cell death via caspase-7 activation. AACR Meeting Abstracts, 3386.
23. Nicholson D.W., and Thornberry N.A. Caspases: killer proteases. Trends Biochem. Sci. 22 (1997) 299-306
24. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., and Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358 (1992) 80-83
25. Phelps M., Phillips A., Darley M., and Blaydes J.P. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J. Biol. Chem. 280 (2005) 16651-16658
26. Ries S., Biederer C., Woods D., Shifman O., Shirasawa S., Sasazuki T., McMahon M., Oren M., and McCormick F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103 (2000) 321-330
27. Schubbert S., Shannon K., and Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7 (2007) 295-308
28. Stommel J.M., and Wahl G.M. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 23 (2004) 1547-1556
29. Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y., El-Deiry W.S., and Yang X. Critical role for Daxx in regulating Mdm2. Nat. Cell Biol. 8 (2006) 855-862
30. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13 (2007) 23-31
31. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
32. Wang H., Nan L., Yu D., Agrawal S., and Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res. 7 (2001) 3613-3624
33. Zhang Z., Li M., Wang H., Agrawal S., and Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad. Sci. USA 100 (2003) 11636-11641
34. Zhang Z., Wang H., Li M., Agrawal S., Chen X., and Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279 (2004) 16000-16006